SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is gaining momentum as investors react to potential breakthroughs in regulatory clarity and institutional adoption, with a highly active community debating its long-term potential as a bridge currency. While some traders are focused on short-term price patterns and the prospect of a short squeeze, many are looking ahead to future financial integration milestones.

Highstreet

Highstreet is trending as traders speculate on a potential short squeeze, fueled by community interest in its low supply and a significant price retracement from recent highs. Investors are actively debating whether current levels represent an accumulation zone for a rebound or a persistent downward trend, with many monitoring whale movements and technical indicators for signs of a turnaround.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing increased community engagement driven by anticipation of its upcoming earnings report and the broader trend of its QNX software becoming foundational for the growing software-defined vehicle and physical AI markets. Long-term investors are highlighting recent contract wins and the company's progress toward sustained profitability as core indicators of long-term value despite ongoing market volatility.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is seeing intense retail-driven momentum as investors speculate on its unique photonic approach to quantum computing and potential for large-scale government funding. The community is actively debating the stock's massive volatility and high short interest, with many weighing long-term growth prospects against concerns over its current valuation and early-stage commercialization.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community debates the significance of the upcoming AACR presentation and the company's long-term survival data. Investors are hyper-focused on potential short-covering and gamma squeeze scenarios driven by options expiration, while vocal bears and bulls clash over the validity of the clinical trial's methodology.

Wix.com Ltd. engages in providing a web development platform for creators, delivering its solutions through a Software-as-a-Service model. Its products include website templates, website builder, website design, Wix features, app market, web hosting, domain names, website accessibility, mobile app builder, and AI website builder. The company was founded by Avishai Abrahami, Nadav Abrahami, Nir Zohar, and Giora Kaplan on October 5, 2006 and is headquartered in Tel Aviv, Israel.

Wix.com Ltd

Wix.com is trending as investors react to a report that Anthropic is preparing to launch an AI-powered design tool, sparking community concerns about potential disruption to the company's core web services business. While some investors view the recent price decline as an exaggerated overreaction and a buying opportunity given the company's aggressive share buybacks, others are actively debating whether AI advances will render traditional website builders obsolete.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing a strong rally alongside a broader cryptocurrency rebound, fueled by massive institutional buying activity and community anticipation of a major supply-driven bull run. Traders are actively debating the stock's structural leverage as a Bitcoin proxy, with bulls highlighting the potential for explosive gains while others remain skeptical of the debt-heavy capital strategy behind these bitcoin acquisitions.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending as defense stocks attract significant capital amidst escalating geopolitical tensions in the Middle East and increased government focus on replenishing military stockpiles. The community is actively discussing the company's role in filling urgent government orders for advanced munitions, alongside speculation regarding its long-term growth potential from potential new production agreements.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as the community debates a potential decoupling from COMEX silver prices, fueled by reports of significant premiums in the Shanghai market and active discussions regarding supply shortages and global production constraints. Traders are intensely focused on short-term technical volatility and mining-specific news, with many analysts highlighting the stock as a high-torque play on the broader precious metals sector.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is gaining significant community attention as investors draw parallels to recent high-profile biotech acquisitions, fueling speculation about its potential as a buyout target due to its de-risked clinical pipeline and substantial cash position. Shareholders are actively discussing positive trial data milestones, the strategic impact of the upcoming Annual Urological Association presentation, and the potential for a short squeeze as they anticipate future BLA filings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Iridian Asset Management LLC CT Sells 9,770 Shares of Axsome Therapeutics, Inc. $AXSM

Iridian Asset Management LLC CT lowered its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 11.7% during the fourth quarter, according to its most recent Form 13F...

UBS Group Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

UBS Group upped their price target on shares of Axsome Therapeutics from $251.00 to $259.00 and gave the stock a "buy" rating in a research report on Friday...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty research firms that are covering the firm, MarketBeat.com reports...

Element Squared LLC Invests $1.48 Million in Axsome Therapeutics, Inc. $AXSM

Element Squared LLC acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and...

Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda

(RTTNews) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Wednesday that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor...

Hennion & Walsh Asset Management Inc. Cuts Stock Position in Axsome Therapeutics, Inc. $AXSM

Hennion & Walsh Asset Management Inc. cut its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 18.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,386 shares of the company's stock after selling 8,530 share...

Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome Therapeutics (NASDAQ:AXSM) Raised to Strong-Buy at Truist Financial

Truist Financial upgraded Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday...

Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Guggenheim Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock

Guggenheim increased their price objective on Axsome Therapeutics from $220.00 to $245.00 and gave the company a "buy" rating in a report on Wednesday...

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

Investors are closely tracking the April 30th decision deadline for Alzheimer’s agitation, betting on a swift approval outcome.

Patients and shareholders are discussing the ongoing real-world clinical success of the flagship drug in treating major depressive disorder.

Optimistic traders are modeling post-approval upside potential, with many eyeing targets between $230 and $300.

Current Price	$188.99
Prev Close	$184.19
Open	$186.91
Dividend Yield	0.00%
50-Day Moving Average	$170.47
Beta	0.74
Avg. Volume	576,010.96
PE Ratio	-51.16

52-Week High	$191.50
52-Week Low	$96.09
Market Capitalization	$9.42B
EPS (Annual)	-$3.68
Price to Book	108.91
Revenue Per Employee	$690,265.95

AXSM
Axsome Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AXSM News

AXSMAxsome Therapeutics Inc